MedPacto Reveals Two Abstracts on 'Bactosertib' at ASCO

"Baektoseotip and Keytruda Combination Therapy Shows 15.2% Response Rate in Clinical Trial"

[Asia Economy Reporter Kim Ji-hee] MedPacto announced on the 20th that the abstracts of clinical data on colorectal cancer and multiple myeloma to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting have been disclosed.

First, in a phase 1b/2a clinical trial combining the anticancer drug under development, "Becatoxertib," and the immuno-oncology drug "Keytruda" in 33 patients with microsatellite stable (MSS) colorectal cancer, an objective response rate (ORR) of 15.2% was reported. This data was obtained from a patient group whose response rate was close to 0% with Keytruda monotherapy. MedPacto stated, "We have sufficiently demonstrated the commercialization potential of Becatoxertib as a combination therapy for MSS colorectal cancer," adding, "Especially compared to currently approved treatments with response rates below 5%, this data is encouraging."

The final poster to be released on the 4th of next month is expected to include clinical data from a larger number of patients than those disclosed in the abstract, as well as overall survival (OS) data for some dosages.

Additionally, MedPacto presented clinical data on multiple myeloma. In a phase 1b clinical trial of Becatoxertib combined with Pomalyst in multiple myeloma patients, a 6-month progression-free survival rate of 80% was recorded, indicating no further cancer progression. This is four times higher compared to 20% with Pomalyst monotherapy.

Since the 6-month progression-free survival rate is 40% when Pomalyst is combined with steroid-based drugs, which are currently used treatments, MedPacto considers this data to be highly meaningful. In particular, MedPacto expects this combination therapy to serve as a new treatment alternative that does not use steroids, addressing unmet medical needs.

A MedPacto representative said, "The colorectal cancer clinical data presented at this conference will serve as an opportunity to confirm the potential to pioneer new markets that Keytruda monotherapy could not overcome," and added, "Becatoxertib has proven its competitiveness as an innovative new drug in hematologic cancers such as multiple myeloma in terms of safety and efficacy."

This content was produced with the assistance of AI translation services.